查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1696288

全球數位化糖尿病管理市場 - 2025 年至 2033 年

Global Digital Diabetes Management Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球數位糖尿病管理市場規模達 145.8 億美元，預計到 2033 年將達到 332.6 億美元，2025-2033 年預測期內的複合年成長率為 9.7%。

全球數位糖尿病管理市場利用設備、軟體和服務等數位技術來改善糖尿病管理和監測。這包括連續血糖監測儀（CGM）、胰島素幫浦、行動應用程式和基於雲端的平台等工具。這些技術共同收集、分析和共享患者健康指標的資料，提供即時見解，使患者和醫療保健提供者能夠就糖尿病管理做出明智的決策。該市場旨在幫助患者更好地控制血糖水平，減少併發症，並改善整體健康。

市場動態：

促進因素與約束因素

糖尿病數位健康領域的技術進步

技術進步在推動數位糖尿病管理市場成長方面發揮關鍵作用。連續血糖監測儀 (CGM)、智慧胰島素幫浦、穿戴式裝置和人工智慧糖尿病管理應用程式等創新正在改變糖尿病的監測和管理方式。這些技術提供有關血糖水平的即時、個人化資料，使患者和醫療保健提供者能夠做出更明智的決策。例如，人工智慧和巨量資料分析有助於改進胰島素輸送演算法並提供個人化的治療建議，改善短期和長期糖尿病管理。

技術進步透過提供有效的糖尿病管理工具徹底改變了糖尿病護理。一個關鍵點是持續維持最佳血糖水平。數位健康工具，包括連網胰島素筆、攜帶式 A1C 監測器和行動應用程式，使患者更容易在醫院外管理糖尿病。這些行動應用程式允許醫療保健提供者根據即時資料創建個人化的治療計劃，確保更好地控制血糖水平並可能降低長期健康風險。

糖尿病管理的另一個突破是自動胰島素輸送（AID）系統，它結合了連續血糖監測儀（CGM）和胰島素泵，可以根據即時血糖資料自動調整胰島素水平。該系統可以更精確地控制血糖水平，並減輕患者的負擔。此外，攜帶式 A1C 監測儀可以讓人們在家中測量他們的 A1C 水平，為評估長期糖尿病控制提供重要指標。這些進步對個人化護理做出了巨大貢獻，使患者能夠更好地管理病情，減少去醫院的次數。

例如，2024 年 2 月，Kakao Healthcare 推出了一款名為 PASTA（個人化、可訪問、支援性、技術支援和實惠）的新型 AI 糖尿病管理應用程式。該應用程式旨在幫助糖尿病和其他慢性疾病患者更有效地管理他們的健康。它與持續血糖監測 (CGM) 設備（例如 i-SENS 的 CareSens Air 和 Dexcom 的 G7）整合，提供血糖水平的即時資料。所有這些因素都要求全球數位化糖尿病管理市場的發展。

設備和技術成本高昂

設備和技術的高成本仍然是全球數位糖尿病管理市場發展的重大限制。根據美國國家生物技術資訊中心 (NCBI) 2024 年 7 月的資料，胰島素幫浦、連續血糖監測儀 (CGM) 和其他先進的數位工具可能非常昂貴，一些胰島素幫浦的價格在 4,500 美元至 6,500 美元之間，不包括相關消耗品。這個價格對患者來說可能是一個障礙，特別是那些沒有醫療保險的患者，限制他們獲得基本糖尿病管理技術。

此外，儘管這些設備透過提供即時資料和更好地控制血糖水平來改善患者的治療效果，但研究表明，與每日多次注射（MDI）相比，胰島素幫浦可能並不總是最具成本效益的選擇，尤其是對於 1 型糖尿病患者而言。因此，全球糖尿病管理市場正在迅速擴張。上述因素限制了市場的成長。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類
  • 按模式分類
  • 最終用戶的程式碼片段
  • 按地區分類

第 3 章：動態

  • 影響因素
    • 驅動程式
      • 糖尿病數位健康領域的技術進步
      • 糖尿病盛行率上升
    • 限制
      • 設備和技術成本高昂
      • 資料隱私和安全問題
    • 機會
      • 新興市場擴張
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 5 章：數位糖尿病管理市場（依產品類型）

  • 智慧型血糖儀
  • 持續血糖監測 (CGM) 系統
  • 智慧胰島素筆
  • 智慧胰島素泵
  • 胰島素貼片和閉迴路泵
  • 其他

第 6 章：數位糖尿病管理市場（按模式分類）

  • 穿戴
  • 手持式

第 7 章：數位糖尿病管理市場（按最終用戶分類）

  • 家庭護理設置
  • 醫院和糖尿病診所
  • 其他

第 8 章：數位糖尿病管理市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
    • 拉丁美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Abbott
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
  • Financial Overview
    • 公司收入
      • 地區收入佔有率
      • 收入預測
      • 關鍵進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
      • SWOT 分析
    • Dexcom 公司
    • F. 霍夫曼-羅氏有限公司
    • 美敦力
    • Insulet 公司。
    • Tandem 糖尿病護理公司
    • Ascensia 糖尿病照護控股公司。
    • LifeScan IP 控股有限責任公司
    • 矩陣
    • Ypsomed AG（非詳盡列表）

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MD2392

The global digital diabetes management market reached US$ 14.58 billion in 2024 and is expected to reach US$ 33.26 billion by 2033, growing at a CAGR of 9.7 % during the forecast period of 2025-2033.

The global digital diabetes management market leverages digital technologies, such as devices, software, and services, to improve diabetes management and monitoring. This includes tools like continuous glucose monitors (CGMs), insulin pumps, mobile apps, and cloud-based platforms. These technologies work together to collect, analyze, and share data on a patient's health metrics, providing real-time insights that enable patients and healthcare providers to make informed decisions about diabetes management. The market aims to empower patients to control their glucose levels better, reduce complications, and improve overall health outcomes.

Market Dynamics: Drivers & Restraints

Technological Advancements in Diabetes Digital Health

Technological advancements play a key role in driving the growth of the digital diabetes management market. Innovations such as continuous glucose monitors (CGMs), smart insulin pumps, wearable devices, and AI-powered diabetes management apps are transforming how diabetes is monitored and managed. These technologies provide real-time, personalized data on blood glucose levels, enabling patients and healthcare providers to make better-informed decisions. For instance, AI and big data analytics help refine insulin delivery algorithms and offer individualized treatment recommendations, improving both short- and long-term diabetes management.

Technological advancements are revolutionizing diabetes care by providing effective tools for managing the condition. One key focus is maintaining optimal glucose levels consistently. Digital health tools, including connected insulin pens, portable A1C monitors, and mobile apps, are making it easier for patients to manage their diabetes outside of hospital settings. These mobile applications allow healthcare providers to create personalized treatment plans based on real-time data, ensuring better control over blood glucose levels and potentially reducing long-term health risks.

Another breakthrough in diabetes management is the automated insulin delivery (AID) system, which combines continuous glucose monitors (CGMs) and insulin pumps to automatically adjust insulin levels based on real-time glucose data. This system offers more precise control over blood sugar levels, reducing the burden on patients. Additionally, portable A1C monitors allow individuals to measure their A1C levels at home, providing an essential marker for assessing long-term diabetes control. These advancements contribute significantly to personalized care, enabling patients to better manage their condition with fewer hospital visits.

For instance, in February 2024, Kakao Healthcare launched a new AI-powered diabetes management app called PASTA (Personalized, Accessible, Supportive, Tech-enabled, and Affordable). This app is designed to help people with diabetes and other chronic conditions manage their health more effectively. It integrates with continuous glucose monitoring (CGM) devices, such as i-SENS's CareSens Air and Dexcom's G7, to provide real-time data on blood glucose levels. All these factors demand the global digital diabetes management market.

High Cost of Devices and Technology

The high cost of devices and technology remains a significant restraint in the global digital diabetes management market. Insulin pumps, continuous glucose monitors (CGMs), and other advanced digital tools can be quite expensive, as per National Center for Biotechnology Information (NCBI) data in July 2024, with some insulin pumps costing between $4,500 and $6,500, not including associated consumables. This price tag can be a barrier for patients, especially those without health insurance, limiting their access to essential diabetes management technology.

Moreover, although these devices improve patient outcomes by providing real-time data and better control over glucose levels, studies have shown that insulin pumps may not always be the most cost-effective option compared to multiple daily injections (MDI), especially for those with type 1 diabetes. As a result, the global diabetes management market is expanding rapidly. The above factors are limiting the market growth.

Segment Analysis

The global digital diabetes management market is segmented based on product type, modality, end-user, and region.

Product Type:

The continuous glucose monitoring (CGM) systems segment from product type is expected to dominate the digital diabetes management market with the highest market share

Continuous glucose monitoring (CGM) systems are a major driver of the growth in the global digital diabetes management market. These devices enable patients to monitor their glucose levels in real time throughout the day without the need for frequent fingerstick testing. CGMs provide critical data on glucose fluctuations, offering patients a comprehensive view of their glucose patterns. This real-time data helps individuals with diabetes make more informed decisions about their insulin dosage, diet, and exercise, contributing to better control over blood sugar levels and fewer complications in the long run.

The increasing accuracy, affordability, and convenience of CGMs have significantly boosted their adoption, especially as these devices now integrate with other diabetes management tools, like insulin pumps and mobile apps. Many CGM systems are now more compact, with advanced features such as alarms for high or low glucose levels, and they often work wirelessly with smartphones, providing patients with accessible and personalized management options.

As more people seek non-invasive, continuous monitoring options, CGMs are becoming a key element in both type 1 and type 2 diabetes management. Their widespread use is a major factor driving the expansion of the digital diabetes management market, particularly as healthcare providers leverage data from CGMs to improve treatment outcomes and patient engagement.

For instance, in August 2024, Medtronic announced FDA approval for its Simplera continuous glucose monitor (CGM), marking a significant innovation in diabetes care. Simplera is Medtronic's first all-in-one, disposable CGM that is half the size of its previous models. Designed for simplicity, it features an easy two-step insertion process, making it ideal for individuals using multiple daily insulin injections (MDI).

It eliminates the need for overtape, offering a more discreet and comfortable wear experience. Additionally, the Simplera system integrates seamlessly with the InPen smart insulin pen and is compatible with Medtronic's MiniMed 780G automated insulin delivery system. These factors have solidified the segment's position in the global digital diabetes management market.

Geographical Analysis

North America is expected to hold a significant position in the global digital diabetes management market with the highest market share

The high prevalence of diabetes in the United States, with nearly 16% of adults diagnosed according to the Centers for Disease Control and Prevention (CDC), is a significant driving factor for the growth of the North American digital diabetes management market.

As the number of diabetes cases continues to rise, there is an increasing demand for effective, efficient, and accessible management solutions. Digital health technologies, such as continuous glucose monitoring (CGM) systems, smart insulin pumps, and mobile apps, offer patients real-time data and personalized feedback that can significantly improve diabetes control, reducing complications associated with the disease.

The integration of AI and machine learning into diabetes management devices allows for smarter, more personalized treatment. These technologies help optimize insulin dosing, offer predictive insights, and reduce the frequency of diabetes-related complications. Moreover, the development of wearable devices, such as insulin pumps and glucose sensors, that are more user-friendly and connected to mobile apps enhances patient engagement and self-management.

For instance, in February 2025, Owens & Minor launched the ByramConnect digital health platform, designed to assist individuals with diabetes and other chronic health conditions. This platform is powered by the Welldoc App, which uses artificial intelligence to provide personalized coaching, self-tracking, and clinically relevant insights. It helps individuals manage conditions like type 1 and type 2 diabetes, as well as related conditions such as hypertension, cardiovascular risks, and weight management

Competitive Landscape

The major global players in the digital diabetes management market include Abbott, Dexcom, Inc., F. Hoffmann-La Roche Ltd, Medtronic, and Insulet Corporation. Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG., LifeScan IP Holdings, LLC., AgaMatrix, and Ypsomed AG among others.

Key Developments

  • In August 2024, Insulet Corporation's Omnipod 5 Automated Insulin Delivery System was FDA-cleared for use by adults with type 2 diabetes, making it the first and only tubeless automated insulin delivery (AID) system approved for both type 1 and type 2 diabetes management.
  • In December 2023, Tandem Diabetes Care launched the full U.S. rollout of its revamped diabetes management platform, Tandem Source. This platform integrates several features from its previous systems, such as t:connect and t:connect HCP, and combines them with enhanced data reporting tools.
  • In August 2023, Welldoc, a digital health leader revolutionizing chronic care, announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar. This clearance immediately follows Welldoc's 10th 510(k) clearance announcement earlier this month, solidifying the company's continued leadership in chronic care innovation.
  • In August 2023, Nemaura Medical's sugarBEAT received approval from the Saudi Food and Drug Authority (SFDA), marking a significant milestone in the Middle East market. This wearable, non-invasive glucose sensor offers continuous glucose monitoring (CGM) for diabetes and pre-diabetes management.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital diabetes management market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Modality
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Technological Advancements in Diabetes Digital Health
      • 3.1.1.2. Rising Prevalence of Diabetes
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Devices and Technology
      • 3.1.2.2. Data Privacy and Security Concerns
    • 3.1.3. Opportunity
      • 3.1.3.1. Expansion in Emerging Markets
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Digital Diabetes Management Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Smart Glucose Meters*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Continuous Glucose Monitoring (CGM) Systems
  • 5.4. Smart Insulin Pens
  • 5.5. Smart Insulin Pumps
  • 5.6. Insulin Patches and Closed-loop Pumps
  • 5.7. Others

6. Digital Diabetes Management Market, By Modality

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 6.1.2. Market Attractiveness Index, By Modality
  • 6.2. Wearable*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Handheld

7. Digital Diabetes Management Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Home Care Settings*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hospitals and Diabetes Clinics
  • 7.4. Others

8. Digital Diabetes Management Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Latin America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Mexico
      • 8.4.6.2. Brazil
      • 8.4.6.3. Argentina
      • 8.4.6.4. Rest of Latin America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Abbott*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
  • 10.2. Financial Overview
    • 10.2.1. Company Revenue
      • 10.2.1.1. Geographical Revenue Shares
      • 10.2.1.1.1. Revenue Forecasts
      • 10.2.1.2. Key Developments
      • 10.2.1.2.1. Mergers & Acquisitions
      • 10.2.1.2.2. Key Product Development Activities
      • 10.2.1.2.3. Regulatory Approvals, etc.
      • 10.2.1.3. SWOT Analysis
    • 10.2.2. Dexcom, Inc.
    • 10.2.3. F. Hoffmann-La Roche Ltd
    • 10.2.4. Medtronic
    • 10.2.5. Insulet Corporation.
    • 10.2.6. Tandem Diabetes Care, Inc.
    • 10.2.7. Ascensia Diabetes Care Holdings AG.
    • 10.2.8. LifeScan IP Holdings, LLC.
    • 10.2.9. AgaMatrix
    • 10.2.10. Ypsomed AG (LIST NOT EXHAUSTIVE)

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us